Evidence map›Paper›PMID 30191762›Full record

ArticleTissue engineering. Part A2019

Augmentation Cystoplasty of Diseased Porcine Bladders with Bi-Layer Silk Fibroin Grafts.

Saif Affas, Frank-Mattias Schäfer, Khalid Algarrahi, Vivian Cristofaro, Maryrose P Sullivan, Xuehui Yang, Kyle Costa, Bryan Sack, Mehrnaz Gharaee-Kermani, Jill A Macoska and 4 more

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering. Part A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Saif Affas1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Frank-Mattias Schäfer1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Khalid Algarrahi1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Vivian Cristofaro3 Division of Urology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts.
Maryrose P Sullivan3 Division of Urology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts.
Xuehui Yang1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Kyle Costa1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Bryan Sack1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Mehrnaz Gharaee-Kermani5 Department of Biological Sciences, Center for Personalized Cancer Therapy, The University of Massachusetts, Boston, Massachusetts.
Jill A Macoska5 Department of Biological Sciences, Center for Personalized Cancer Therapy, The University of Massachusetts, Boston, Massachusetts.
Gokhan Gundogdu1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Catherine Seager1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Carlos R Estrada1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Joshua R Mauney1 Department of Urology, John F. Enders Research Laboratories, Boston Children's Hospital, Boston, Massachusetts.
Boston Children's Hospital · USHarvard University · USCenter for Personalized Cancer Treatment · NLVA Boston Healthcare System · US

Funding

UMass Boston-DF/HCC U54 Partnership (2 of 2)U54CA156734 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI ADAN COLON-CARMONA, Jill A. Macoska · 2010 to 2026
$24.9M
Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
Role of Beta-Catenin in Urinary DysfunctionU54DK104310 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI MACOSKA, JILL A., MARKER, PAUL C · 2014 to 2023
$12.8M
Development of Silk Fibroin Grafts for Reconstruction of Pathological BladdersR21EB020860 · NIBIB · BOSTON CHILDREN'S HOSPITAL · PI ESTRADA, CARLOS R, MAUNEY, JOSHUA ROBERT · 2015 to 2016
$486k
Effect of Type II Diabetes on Bladder FunctionI01BX001790 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MARYROSE P SULLIVAN · 2013 to 2026
–
BLRD VA I01 BX001790NCI NIH HHS U54 CA156734NIBIB NIH HHS P41 EB002520NIBIB NIH HHS R21 EB020860NIDDK NIH HHS U54 DK104310
6 · The paper itself

Abstract

impact statementThe search for an ideal "off-the-shelf" biomaterial for augmentation cystoplasty remains elusive and current scaffold configurations are hampered by mechanical and biocompatibility restrictions. In addition, preclinical evaluations of potential scaffold designs for bladder repair are limited by the lack of tractable large animal models of obstructive bladder disease that can mimic clinical pathology. The results of this study describe a novel, minimally invasive, porcine model of partial bladder outlet obstruction that simulates clinically relevant phenotypes. Utilizing this model, we demonstrate that acellular, bi-layer silk fibroin grafts can support the formation of vascularized, innervated bladder tissues with functional properties.

Indexed as

RegenerationUrinary Bladder DiseasesAnimalsDisease Models, AnimalFemaleFibroinsSwineTissue ScaffoldsUrodynamicsFibroinsbladderregenerationsilk fibroin

Identifiers

PMID30191762
PMCPMC6589503
OpenAlexW2891516625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.